within Pharmacolibrary.Drugs.ATC.B;

model B01AA12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.0023333333333333335,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Fluindione is a vitamin K antagonist anticoagulant (coumarin derivative) that was historically used for the prevention and treatment of thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. It has been largely withdrawn or replaced by other anticoagulants in most countries and is not widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical adult following oral administration (estimates; no referenced clinical PK source found).</p><h4>References</h4><ol><li><p>Comets, E, et al., &amp; Mentré, F (2012). Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians. <i>Clinical pharmacology and therapeutics</i> 91(5) 777–786. DOI:<a href=&quot;https://doi.org/10.1038/clpt.2011.309&quot;>10.1038/clpt.2011.309</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22472992/&quot;>https://pubmed.ncbi.nlm.nih.gov/22472992</a></p></li><li><p>Warot, D, et al., &amp; Diquet, B (2000). Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects. <i>Fundamental &amp; clinical pharmacology</i> 14(3) 231–236. DOI:<a href=&quot;https://doi.org/10.1111/j.1472-8206.2000.tb00021.x&quot;>10.1111/j.1472-8206.2000.tb00021.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15602800/&quot;>https://pubmed.ncbi.nlm.nih.gov/15602800</a></p></li><li><p>Cullell, N, et al., &amp; Fernandez-Cadenas, I (2018). Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants. <i>Oncotarget</i> 9(49) 29238–29258. DOI:<a href=&quot;https://doi.org/10.18632/oncotarget.25579&quot;>10.18632/oncotarget.25579</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30018749/&quot;>https://pubmed.ncbi.nlm.nih.gov/30018749</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AA12;
